BaseClear BV Certified to Provide NimbleGen Sequence Capture Services in the Netherlands

MADISON, Wis.--(BUSINESS WIRE)-- Roche NimbleGen, a Roche (SWX:RO)(SWX:ROG)(Pink Sheets:RHHBY) Company announced today that the Netherlands-based genomic service provider BaseClear BV has officially joined the Roche NimbleGen Certified Service Provider (CSP) Program. BaseClear has been certified to process customer samples using the NimbleGen SeqCap EZ Library (solution phase) workflow for next-generation sequencing, most specifically using SeqCap EZ Exome version 2.0 products, in their lab in Leiden. They passed a rigorous certification test plan to achieve precise experimental standards to officially join the Roche NimbleGen CSP Program. BaseClear is the first Certified Service Provider for this application in Europe and the second provider worldwide.

“We are very pleased to join the Roche NimbleGen CSP program, which complements our existing accreditations and certifications. BaseClear always strives to deliver the highest level of service to our customers”, said Bas Reichert, commercial director of BaseClear. “I am proud that we are the first company in Europe as a Roche NimbleGen Certified Service Provider for SeqCap EZ Library. With the Nimblegen SeqCap EZ Exome capture system we can extend our service portfolio and will be able to deliver a high quality and cost effective solution to the human genetics research community. The certification is an additional guarantee for our high quality standard, clearly outlines our commitment to providing the best possible exome capture service, and ensures that we will have early access to new product variants and improvements.”

“Roche NimbleGen is pleased to welcome BaseClear as the first European certified service provider of our SeqCap EZ application. BaseClear’s commitment to high-quality genomic and sequencing services in the Netherlands is key in providing researchers with access to cutting edge genomic tools such as the NimbleGen SeqCap EZ Workflow in the Benelux region" said Dr. Frank Pitzer, CEO of Roche NimbleGen, Inc.

For more information about Roche NimbleGen, please visit www.nimblegen.com

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80’000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

About BaseClear BV
BaseClear is a leading genomic service provider based in Leiden, The Netherlands. Within our ISO/IEC 17025 accredited laboratory setting we offer services for DNA-based research, quality assurance and forensics. For all areas in which DNA plays a key role, BaseClear offers several services in the form of convenient and high-quality solutions that can be tailored exactly to customer wishes. For more information about BaseClear BV, please visit www.baseclear.com.

SeqCap EZ products are for life science research only. Not for use in diagnostic procedures.

NIMBLEGEN and SEQCAP are trademarks of Roche.

Other brands or product names are trademarks of their respective holders.

All trademarks used or mentioned in this release are protected by law.



CONTACT:

Roche Diagnostics
Dr. Burkhard Ziebolz
Phone: +49 8856 604830
Email: [email protected]
or
Roche NimbleGen
Kary Staples
Phone: +1 608 218 7623
Email: [email protected]
or
BaseClear BV
Drs. Bas Reichert
Commercial director
Phone : +31 71 5233917
Email : [email protected]
or
Dr. Derek Butler
Head Genome analysis services
Phone : +31 71 5233917
Email : [email protected]

KEYWORDS:   United States  Europe  North America  Netherlands  Switzerland  Wisconsin

INDUSTRY KEYWORDS:   Stem Cells  Health  Biotechnology  Genetics  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."